Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | ETV6 | P41212 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585871 | 0.91 | PLK4 (0.54) | LRRK2KDRETV6AURKAPLK4 | |
| SCHEMBL3793333 | 0.81 | PLK4 (0.51) | LRRK2KDRETV6NTRK1AURKA | |
| SCHEMBL12848144 | 0.81 | PLK4 (0.51) | LRRK2KDRETV6NTRK1AURKA | |
| SCHEMBL3793328 | 0.81 | PLK4 (0.51) | LRRK2KDRETV6NTRK1AURKA | |
| SCHEMBL19928100 | 0.80 | PLK4 (0.55) | LRRK2KDRETV6NTRK1AURKA | |
| SCHEMBL3717265 | 0.79 | TTK (0.52) | LRRK2KDRAURKAPLK4FLT3 | |
| SCHEMBL3242110 | 0.78 | ALDH1A1 (0.55) | ALKTDO2 | |
| SCHEMBL3710632 | 0.78 | TTK (0.52) | LRRK2KDRETV6PLK4FLT3 | |
| SCHEMBL14208177 | 0.78 | ALDH1A1 (0.48) | LRRK2MAP4K1JAK2 | |
| SCHEMBL19928117 | 0.77 | PLK4 (0.58) | LRRK2KDRETV6NTRK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| CN-101970426-A | Indazolyl-, benzimidazolyl-, benzotriazolyl-substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIV HEALTH NETWORK | 2011-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | LRRK2 254/4885KDR 679/4885ETV6 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.